Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease.

Publication date: Mar 26, 2025

By assessing the standard-of-care regimen for tuberculosis (TB) in BALB/c and C3HeB/FeJ mice, we demonstrate that rifampin, with or without pyrazinamide, is essential for an effective bactericidal response and suppression of resistance. Potency measurements in an in vitro lipid-rich model and a rabbit caseum assay recapitulate the significance of rifampin as a sterilizing agent. These outcomes align with clinical performance, thus emphasizing the value of in vitro predictive tools and murine TB models with human-like pathology.

Open Access PDF

Concepts Keywords
Bactericidal C3HeB/FeJ
Clinical caseum
Mice relapse
Rich rifafour
Tuberculosis tuberculosis

Semantics

Type Source Name
disease IDO bactericidal
disease MESH tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK Rifampicin
drug DRUGBANK Pyrazinamide
disease IDO assay
disease MESH relapse
drug DRUGBANK Isoniazid
drug DRUGBANK Ethambutol
disease IDO bacteriostatic
disease MESH granulomas
disease IDO susceptibility
drug DRUGBANK Butyric Acid
disease IDO bacteria
drug DRUGBANK Ilex paraguariensis leaf
disease MESH infection
drug DRUGBANK Activated charcoal
disease MESH drug interactions
pathway REACTOME Translation
drug DRUGBANK Etoperidone
drug DRUGBANK Dimethyl sulfoxide
disease MESH Allergy
disease MESH Infectious Diseases
drug DRUGBANK Moxifloxacin
drug DRUGBANK Bedaquiline
disease MESH drug tolerance
disease MESH pulmonary tuberculosis
drug DRUGBANK Carboxyamidotriazole

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *